Ali Khademhosseini

Ali Khademhosseini (, born October 30, 1975, Tehran, Iran) is the CEO of the Terasaki Institute, non-profit research organization in Los Angeles, and Omeat Inc., a cultivated-meat startup.

Before taking his current CEO roles, he spent one year at Amazon Inc.

Prior to that he was the Levi Knight chair and professor at the University of California-Los Angeles where he held a multi-departmental professorship in Bioengineering, Radiology, Chemical, and Biomolecular Engineering as well as the Director of Center for Minimally Invasive Therapeutics (C-MIT).

From 2005 to 2017, he was a professor at Harvard Medical School, and the Wyss Institute for Biologically Inspired Engineering.

He is an academic entrepreneur who has made contributions in biomaterials and regenerative medicine, particular for developing hydrogels for tissue engineering and bioprinting.

He has started multiple companies, including Obsidio Inc. (sold to Boston Scientific) and Omeat Inc.

His studies have been cited over 124,900 times (H index = 181).

He received his Ph.D. in bioengineering from MIT under the supervision of Robert S. Langer (2005), and MASc (2001) and BASc (1999) degrees from the University of Toronto both in chemical engineering.

Dr. Khademhosseini is a leader in developing ‘personalized’ solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease, and cancer.

For example, he has developed numerous techniques for controlling the behavior of patient-derived cells to engineer artificial tissues and cell-based therapies.

He is also developing ‘organ-on-a-chip’ systems that mimic human physiology and pathology to enable patient-specific evaluation of drug candidates.

In addition, his laboratory is utilizing biofabrication to form vascularized tissues with appropriate microarchitectures and regulate stem cell differentiation in microengineered environments.

He has also developed various high-performance biomaterials for numerous applications in tissue engineering and regenerative medicine.

For example, he has developed and popularized gelatin methacryloyl (GelMA) which has become one of the main materials for 3D bioprinting industry.

He also developed electrically conductive, tunable hydrogels by mixing GelMA with nanomaterials, including gold nanoparticles and carbon-based nanomaterials.

He has demonstrated the use of GelMA-based materials for tissue engineering and other clinical applications such as sealants and hemostats.

He has also made advancements in new 3D bioprinters.

In one example, he has developed an innovative multi-nozzle, multi-material bioprinter.

In another example, he has engineered stereolithography-based bioprinters.

He has developed different bioinks for various tissue engineering applications.

Another area of focus has been on building multi-organ on-a-chip systems with integrated in-line sensors.

Such devices are finding use in the next generation of organs on a chip systems.

His early work in electrochemical biosensors with regeneration ability and microfluidic physical sensors allowed in-line monitoring of organs-on-a-chip platforms.

He was also one of the pioneers of smart patches for chronic wound healing, where both sensing the wound and the rapid drug intervention was conducted using the same device.

He has also made key contributions to vascularizing thick tissues with technologies including sacrificial molding, bioprinting, and microengineering.

He has edited multiple books/journal special issues and is an author on >700 peer-reviewed journal articles, editorials, review papers, >70 book chapters/edited books, and >50 patent/disclosure applications.

His work has been published in leading journals and routinely highlighted in international media.

Khademhosseini is an academic entrepreneur who has started multiple companies to translate the findings of his research into products.

He combined silica nanoparticles with gelatin to engineer shear-thinning materials for the embolization of blood vessels in the peripheral vasculature.

He then co-founded Obsidio Medical to pursue clinical applications of this breakthrough.

The technology was approved by U.S. Food and Drug Administration, and Obsidio Medical was acquired by Boston Scientific in August 2022.

He also founded Omeat Inc., aiming to produce cultivated meat in a scalable and affordable manner.

Omeat is a vertically integrated meat company that also produces humane and cost effective fetal bovine serum replacement.

Dr. Khademhosseini's interdisciplinary research has been recognized over 70 major national and international awards.

In 2007, he was named a TR35 recipient by the MIT Technology Review magazine as one of the world's top young innovators.

He is a recipient of the 2011 Presidential Early Career Award for Scientists and Engineers (PECASE) by President Barack Obama, the highest honor given by the US government for early-career investigators.

Khademhosseini is a recipient of the Massachusetts Institute of Technology Outstanding Undergraduate mentor award.

Every year since 2014 he has been selected by Thomson Reuters as one of the World's Most Influential Minds.

By the number of citations, he is the most cited author of in various journals in the field of biomaterials like Biomaterials, Advanced Healthcare Materials, Biofabrication, Tissue Engineering - Part B: Reviews.

Khademhosseini was born in Tehran, Iran, and grew up in Toronto, Canada.